The National Comprehensive Cancer Network (NCCN) Guidelines for Kidney Cancer focus on the screening, diagnosis, staging, treatment, and management of renal cell carcinoma (RCC). All systemic kidney cancer therapy regimens were categorized to provide guidance on treatment selection by considering the efficacy, safety, evidence, and other factors that play a role in treatment selection. These factors include comorbidities, nature of the disease, access to agents and hereditary genetic risk.
These updated guidelines include criteria for further genetic risk evaluation using a hereditary cancer panel for hereditary RCC syndromes:
· Close family history of known pathogenic variations or cancer,
· Diagnosed before the age of 46,
· Bilateral or multifocal tumors OR
· Tumors with certain histological characteristics.
The panels are recommended to contain
VHL, MET, FLCN, TSC1, TSC2, FH, BAP1, SDHA, SDHB, SDHC and SDHD.
Genetics Institute of America’s GIAnomics™ Hereditary Cancer Panel includes all the recommended predisposition genes for RCC. GIA is committed to exceeding the standards put forth by prestigious organizations, like NCCN, and ensuring that the panels we offer support your medical needs and your patient’s health and safety.